Perazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Perazine
Accession Number
DB12710
Type
Small Molecule
Groups
Investigational
Description

Perazine has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
8915147A2B
CAS number
84-97-9
Weight
Average: 339.5
Monoisotopic: 339.176918991
Chemical Formula
C20H25N3S
InChI Key
WEYVCQFUGFRXOM-UHFFFAOYSA-N
InChI
InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3
IUPAC Name
10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=CC=CC=C23)CC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePerazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetaminePerazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetaminePerazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePerazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Perazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Perazine.Experimental
AcebutololPerazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Perazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Perazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Perazine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Perazine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Perazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Perazine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Perazine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Perazine.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Perazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Perazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perazine.Approved, Illicit, Investigational
AlprenololPerazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmisulpridePerazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Perazine.Approved, Illicit
AmodiaquineThe serum concentration of Perazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Perazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Perazine.Experimental
AmphetaminePerazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perazine.Approved, Investigational
ArotinololPerazine may increase the hypotensive activities of Arotinolol.Investigational
ArtemetherThe serum concentration of Perazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Perazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Perazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Perazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Perazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Perazine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Perazine.Approved
AtenololPerazine may increase the hypotensive activities of Atenolol.Approved
AtovaquoneThe serum concentration of Perazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Perazine.Investigational, Vet Approved
AzelastinePerazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Perazine.Illicit
BefunololPerazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Perazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Perazine.Approved
BenzphetaminePerazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Perazine.Approved
BetaxololPerazine may increase the hypotensive activities of Betaxolol.Approved
BevantololPerazine may increase the hypotensive activities of Bevantolol.Approved
BezitramidePerazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololPerazine may increase the hypotensive activities of Bisoprolol.Approved
BopindololPerazine may increase the hypotensive activities of Bopindolol.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perazine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Perazine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Perazine.Investigational
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Perazine.Approved, Investigational, Withdrawn
BucindololPerazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolPerazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perazine.Approved, Investigational
BupranololPerazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphinePerazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Perazine.Vet Approved
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Perazine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Perazine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perazine.Approved, Illicit, Vet Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Perazine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Perazine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Perazine.Illicit, Investigational, Vet Approved
CarteololPerazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolPerazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPerazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perazine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Perazine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perazine.Approved
ChloroquineThe serum concentration of Perazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenterminePerazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Perazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perazine.Approved, Investigational, Withdrawn
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perazine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Perazine is combined with Citalopram.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Perazine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Perazine is combined with Clomipramine.Approved, Vet Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Perazine is combined with Clopenthixol.Experimental
CloranololPerazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Perazine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Perazine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Perazine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Perazine.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perazine.Approved
Cycloguanil embonateThe serum concentration of Perazine can be increased when it is combined with Cycloguanil embonate.Experimental
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Perazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Perazine can be increased when it is combined with Dapsone.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Perazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Perazine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Perazine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Perazine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perazine.Approved, Vet Approved
DextroamphetaminePerazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Perazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Perazine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Perazine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Perazine is combined with Diethyl ether.Experimental
DiethylpropionPerazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perazine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perazine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Perazine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perazine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Perazine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Perazine.Vet Approved
DoxycyclineThe serum concentration of Perazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Perazine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Perazine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Perazine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Perazine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Perazine.Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Perazine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Perazine.Approved, Investigational, Vet Approved
EpanololPerazine may increase the hypotensive activities of Epanolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Perazine is combined with Escitalopram.Approved, Investigational
EsmololPerazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Perazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perazine.Approved
EthanolPerazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perazine.Approved, Illicit, Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perazine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Perazine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Perazine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Perazine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Perazine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Perazine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Perazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Perazine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Perazine.Illicit, Vet Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Perazine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Perazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perazine.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Perazine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Perazine.Approved, Illicit
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Perazine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Perazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perazine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perazine.Approved, Investigational
FluvoxamineThe risk or severity of adverse effects can be increased when Perazine is combined with Fluvoxamine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Perazine.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Perazine.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Perazine.Approved, Illicit, Investigational
GepefrinePerazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Perazine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Perazine.Approved, Illicit
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Perazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Perazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Perazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Perazine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Perazine.Approved
HydrocodonePerazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyamphetaminePerazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Perazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Perazine is combined with Indalpine.Investigational, Withdrawn
IndenololPerazine may increase the hypotensive activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Perazine.Investigational
Iofetamine I-123Perazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Perazine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Perazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Perazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perazine.Approved, Investigational
LabetalolPerazine may increase the hypotensive activities of Labetalol.Approved
LandiololPerazine may increase the hypotensive activities of Landiolol.Investigational
LevobunololPerazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Perazine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Perazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perazine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Perazine.Approved, Vet Approved
LisdexamfetaminePerazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Perazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Perazine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Perazine is combined with Loprazolam.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Perazine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perazine.Approved
LumefantrineThe serum concentration of Perazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perazine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MebicarThe risk or severity of adverse effects can be increased when Perazine is combined with Mebicar.Experimental
MedazepamThe risk or severity of adverse effects can be increased when Perazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Perazine.Vet Approved
MefloquineThe serum concentration of Perazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Perazine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Perazine.Approved, Investigational
MephedronePerazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePerazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololPerazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perazine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Perazine is combined with Meptazinol.Experimental
MequitazinePerazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perazine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Perazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Perazine.Approved, Illicit
MethamphetaminePerazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Perazine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Perazine.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Perazine.Approved
MethotrimeprazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perazine.Approved, Investigational, Vet Approved
MethoxyphenaminePerazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Perazine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Perazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perazine.Approved
MetipranololPerazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perazine.Approved, Investigational
MetoprololPerazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePerazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Perazine.Approved, Illicit
MidomafetaminePerazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Perazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Investigational
MirtazapinePerazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineThe serum concentration of Perazine can be increased when it is combined with Mizoribine.Investigational
MMDAPerazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Perazine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Perazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved, Investigational
NadololPerazine may increase the hypotensive activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perazine.Approved
NebivololPerazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Perazine is combined with Nefazodone.Approved, Withdrawn
NicomorphinePerazine may increase the hypotensive activities of Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Perazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Perazine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Perazine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Perazine.Approved, Illicit
OlanzapineThe risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine.Approved, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Perazine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Perazine.Approved, Illicit
OrphenadrinePerazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Perazine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perazine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Perazine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Perazine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perazine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perazine.Approved
ParaldehydePerazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Perazine is combined with Paroxetine.Approved, Investigational
PenbutololPerazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Perazine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Perazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Perazine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Perazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Perazine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Perazine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Perazine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Perazine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Perazine.Approved
PhenterminePerazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Perazine.Approved
PindololPerazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Perazine.Approved, Investigational
PiperaquineThe serum concentration of Perazine can be increased when it is combined with Piperaquine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Perazine.Investigational
Platelet Activating FactorPerazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
PractololPerazine may increase the hypotensive activities of Practolol.Approved
PramipexolePerazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Perazine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Perazine.Approved, Illicit
PregabalinThe therapeutic efficacy of Perazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Perazine.Approved
PrimaquineThe serum concentration of Perazine can be increased when it is combined with Primaquine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Perazine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perazine.Approved, Vet Approved
ProguanilThe serum concentration of Perazine can be increased when it is combined with Proguanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Perazine.Approved, Vet Approved
PropanididThe risk or severity of adverse effects can be increased when Perazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Perazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Perazine.Approved
PropranololPerazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProxibarbalThe risk or severity of adverse effects can be increased when Perazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Perazine.Investigational
PseudoephedrinePerazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Perazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Perazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Perazine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perazine.Approved
QuinacrineThe serum concentration of Perazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Perazine.Approved
QuinidineThe serum concentration of Perazine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Perazine can be increased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Perazine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Perazine.Investigational
RadicicolThe serum concentration of Perazine can be increased when it is combined with Radicicol.Experimental
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perazine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perazine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Perazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Perazine.Investigational
RitobegronPerazine may decrease the stimulatory activities of Ritobegron.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Perazine.Vet Approved
RopinirolePerazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perazine.Approved
RotigotinePerazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Perazine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perazine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Perazine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Perazine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Perazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perazine.Approved, Vet Approved
SinefunginThe serum concentration of Perazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved
SotalolPerazine may increase the hypotensive activities of Sotalol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perazine.Approved, Investigational
SulfadoxineThe serum concentration of Perazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Perazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpiridePerazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Perazine is combined with Sultopride.Experimental
SuvorexantPerazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TafenoquineThe serum concentration of Perazine can be increased when it is combined with Tafenoquine.Investigational
TalinololPerazine may increase the hypotensive activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Perazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Perazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Perazine.Approved
TertatololPerazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Perazine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Perazine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Perazine.Investigational
ThalidomidePerazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perazine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Perazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perazine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Perazine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Perazine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Perazine is combined with Tilidine.Experimental
TimololPerazine may increase the hypotensive activities of Timolol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Perazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Perazine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perazine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Perazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Perazine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Perazine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Perazine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Perazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Perazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TromethamineTromethamine can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Perazine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Perazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Perazine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Perazine is combined with Veralipride.Experimental
VilazodoneThe risk or severity of adverse effects can be increased when Perazine is combined with Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Perazine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Perazine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Perazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Perazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Perazine.Approved, Illicit, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Perazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Perazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Perazine.Vet Approved
ZolpidemPerazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Perazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Perazine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perazine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C16903
PubChem Compound
4744
PubChem Substance
347828908
ChemSpider
4582
ChEBI
59118
ChEMBL
CHEMBL1697766
PharmGKB
PA162565876
ATC Codes
N05AB10 — Perazine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0601 mg/mLALOGPS
logP4.19ALOGPS
logP3.78ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)8.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105 m3·mol-1ChemAxon
Polarizability39.53 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-01w4-3932000000-826fc2cac2d9f88605f2
GC-MS Spectrum - CI-BGC-MSsplash10-0002-9310000000-ec3169ce94eacf892f47
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / N-methylpiperazines / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / N-alkylpiperazine / N-methylpiperazine / 1,4-diazinane / Piperazine / Para-thiazine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, N-alkylpiperazine, N-methylpiperazine (CHEBI:59118)

Drug created on October 20, 2016 17:43 / Updated on December 01, 2017 16:32